MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Presynaptic dopaminergic system"

  • 2019 International Congress

    Comparison of PDE10A and DAT expression as markers of disease burden in early Parkinson’s disease

    G. Pagano, H. Wilson, T. Yousaf, F. Niccolini, N. Khan, D. Martino, R. Gunn, E. Rabiner, P. Piccini, T. Foltynie, M. Politis (London, United Kingdom)

    Objective: We aimed to compare loss of PDE10A and DAT expression in patients with Parkinson’s disease. Background: Recent work has shown loss of PDE10A expression…
  • 2018 International Congress

    Biofabricated tissue constructs to recapitulate the anatomy and functionality of the nigrostriatal pathway in Parkinson’s disease

    J. Duda, L. Struzyna, K. Browne, H. Chen, D. Cullen (Philadelphia, PA, USA)

    Objective: 1) Biofabricate constructs that mimic the cytoarchitecture and function of the nigrostriatal pathway, and 2) Microinject constructs to assess restoration of dopaminergic input to…
  • 2018 International Congress

    Does dopaminergic denervation of specific anatomical regions of the basal ganglia correlate with clinical features of Parkinsonism: A quantitative DaTscan study

    M. Salgado, S. Aggarwal, J. Muller, S. Singh, D. Ney (Brooklyn, NY, USA)

    Objective: To correlate different clinical features of parkinsonism with regional variations of presynaptic dopaminergic dysfunction of the basal ganglia using quantitative DaTscans. Background: DaT-SPECT imaging…
  • 2018 International Congress

    Putaminal dopamine depletion in de novo Parkinson’s disease predicts future development of wearing-off

    S.J. Chung, Y. Lee, J.S. Oh, J.S. Kim, P.H. Lee, Y.H. Sohn (Goyang, Republic of Korea)

    Objective: The present study aimed to investigate whether the level of presynaptic dopamine neuronal loss predicts future development of wearing-off in de novo Parkinson’s disease.…
  • 2018 International Congress

    Neuroinflammation Predicts Dompaminergic Deficit in Early Parkinson Disease: DAT SPECT Imaging Study

    F. Rahmani, M. Rahmani (Tehran, Islamic Republic of Iran)

    Objective: We aimed to investigate whether striatal Dopamine transporter (DaT) uptake could be predicted by Neutrophil to lymphocyte ratio (NLR) or measures of disease severity…
  • 2017 International Congress

    Relationship between cognitive dysfunction and striatal uptake of 123I-FP-CIT in patients with Parkinson’s disease

    H. Sawada, S. Orimo, A. Inaba, M. Takahashi (Tokyo, Japan)

    Objective: The objective of this study is to investigate a relationship between cognitive dysfunction and striatal uptake of 123I-FP-CIT SPECT (dopamine transporter (DAT) SPECT) in…
  • 2017 International Congress

    Associations of DAT SPECT and TCS with prodromal features of Parkinson’s disease: results in PREDICT-PD participants

    A. Noyce, J. Dickson, J. Bestwick, I. Isaias, M. Politis, G. Giovannoni, T. Warner, A. Lees, A. Schrag (London, United Kingdom)

    Objective: To examine whether changes on dopamine reuptake transporter (DAT) SPECT and transcranial sonography (TCS) correlated with Parkinson’s disease (PD) risk scores and other prodromal…
  • 2017 International Congress

    SPECT imaging of striatal DAT availability in Parkinson’s: changes over time and relevance to dyskinesias

    A.-A. Roussakis, D. Towey, P. Piccini (London, United Kingdom)

    Objective: This study was designed to explore in Parkinson’s disease (PD) the role of dopamine transporter (DAT)-specific single photon emission computed tomography (SPECT) imaging as a…
  • 2017 International Congress

    Early caudate involvement in Parkinson’s disease may predict future cognitive decline

    R. Durcan, D. Brooks, D. Burn, N. Pavese (Newcastle Upon Tyne, United Kingdom)

    Objective: 1. To investigate prevalence of caudate dopaminergic dysfunction as measured by 123I-FP-CIT in a large cohort of early stage (< 2 years disease duration)…
  • 2017 International Congress

    Global Regulatory Agencies Support the Use of Dopamine Transporter Neuroimaging for Subject Selection in Clinical Trials Targeting Early Stage Parkinson’s Disease – on behalf of Critical Path for Parkinson’s (CPP) Consortium

    D. Stephenson, J. Cedarbaum, J. Eberling, M. Facheris, D. Grosset, M. Gordon, D. Hill, S. Imam, V. Kern, G. Klein, D. Matthews, P. Muglia, A. Roach, K. Romero, D. Russell, J. Seibyl, L. Slieker, E. Somer, C. Sur, Z. Xie, K. Marek (Tucson, AZ, USA)

    Objective: A key goal of the Critical Path for Parkinson’s Consortium (CPP) is to qualify, with regulatory agencies, drug development tools for use in PD…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • To be or not to bupropion: a drug-induced parkinsonism?
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley